| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/27/2006 | EP1735305A2 3-quinuclidinyl heteroatom bridged biaryl derivatives |
| 12/27/2006 | EP1735304A1 Quinolinone-carboxamide compounds as 5-ht4 receptor agonists |
| 12/27/2006 | EP1735303A2 1,3,4-oxadiazol-2-ones as ppar delta modulators and their use thereof |
| 12/27/2006 | EP1735302A1 4-amino-piperidine derivatives as monoamine uptake inhibitors |
| 12/27/2006 | EP1735301A1 Pyridine derivatives as cannabinoid receptor modulators |
| 12/27/2006 | EP1735300A1 Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives |
| 12/27/2006 | EP1735299A1 Tertrahydrobenzazepines as histamine h3 receptor ligands |
| 12/27/2006 | EP1735298A1 Piperidine derivates for the treatment of chemokines mediared disease |
| 12/27/2006 | EP1735296A1 Materials and methods for treating coagulation disorders |
| 12/27/2006 | EP1735295A1 Antiinflammatory lactones |
| 12/27/2006 | EP1735294A1 Thiadiazole-amine compounds for the treatment of neurodegenerative disorders |
| 12/27/2006 | EP1735293A2 Substituted hydroxyethylamine aspartyl protease inhibitors |
| 12/27/2006 | EP1735292A1 Thiazole-amine compounds for the treatment of neurodegenerative disorders |
| 12/27/2006 | EP1735288A1 Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders |
| 12/27/2006 | EP1735287A1 Therapeutic agents |
| 12/27/2006 | EP1735286A1 Tetrahydro-indazole cannabinoid modulators |
| 12/27/2006 | EP1735285A2 Pyrazole-amine compounds for the treatment of neurodegenerative disorders |
| 12/27/2006 | EP1735284A1 N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides |
| 12/27/2006 | EP1735282A1 Pyrazole compounds and uses related thereto |
| 12/27/2006 | EP1735281A2 Synthesis of indenoisoquinoliniums and methods of use |
| 12/27/2006 | EP1735280A1 Aryl sulfonamide and sulfonyl compounds as modulators of ppar and methods of treating metabolic disorders |
| 12/27/2006 | EP1735279A1 Prolinyl derivates for treating thrombosis |
| 12/27/2006 | EP1735278A1 Histamine h3 receptor agents, preparation and therapeutic uses |
| 12/27/2006 | EP1735277A1 2-alkylidene-18,19-dinor-vitamin d compounds |
| 12/27/2006 | EP1735275A2 Aryl sulfones and uses related thereto |
| 12/27/2006 | EP1735274A1 Nonpeptide inhibitors of matrix metalloproteinases |
| 12/27/2006 | EP1735271A2 Compounds for modulating the glycolysis enzyme complex and/or the transaminase complex |
| 12/27/2006 | EP1735270A1 Diamino alcohols and their use as renin inhibitors |
| 12/27/2006 | EP1735268A1 Opioid receptor antagonists |
| 12/27/2006 | EP1735069A1 Extraction process |
| 12/27/2006 | EP1735057A2 Method and compositions for treatment of chronic neuropathic pain |
| 12/27/2006 | EP1735056A2 Extended cycle multiphasic oral contraceptive method |
| 12/27/2006 | EP1735055A1 Method of reducing c-reactive protein using growth hormone secretagogues |
| 12/27/2006 | EP1735024A1 Process and systems for biocompatible surfaces |
| 12/27/2006 | EP1735010A2 Methods, compositions, and preparations for delivery of immune response modifiers |
| 12/27/2006 | EP1735009A2 iRNA AGENTS TARGETING VEGF |
| 12/27/2006 | EP1735007A2 Cyclodextrin inclusion complexes of pyrimidine-2,4,6-triones |
| 12/27/2006 | EP1735003A2 Pharmaceutical compositions based on anticholinergics and ccr2 receptor antagonists |
| 12/27/2006 | EP1735002A2 Cancer therapy comprising a nuclear receptor ligand and a hdac inhibitor |
| 12/27/2006 | EP1735001A2 Pharmaceutical compositions for the treatment of skin diseases comprising a combination of epinastine and one or more additional minerals or one or more crude drugs |
| 12/27/2006 | EP1735000A2 Method for augmenting b cell depletion |
| 12/27/2006 | EP1734999A2 Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure |
| 12/27/2006 | EP1734998A2 Compositions and methods comprising an egfl7 antagonist for modulating vascular development |
| 12/27/2006 | EP1734997A2 Steroid sparing agents and methods of using same |
| 12/27/2006 | EP1734987A2 Interferon-beta for anti-virus therapy for respiratory diseases |
| 12/27/2006 | EP1734984A2 Compositions and methods for topical diagnostic and therapeutic transport |
| 12/27/2006 | EP1734980A1 Use of peptidic compounds for the prophylaxis and treatment of chronic headache |
| 12/27/2006 | EP1734976A1 Extracts of scutellaria for the treatment of sars |
| 12/27/2006 | EP1734974A1 D-ribose for improving depression-like symptoms |
| 12/27/2006 | EP1734972A2 Method of treating solid tumors and leukemias using combination therapy of vitamin d and anti-metabolic nucleoside analogs |
| 12/27/2006 | EP1734971A1 Polymer-based sustained release device |
| 12/27/2006 | EP1734970A2 Treatment of fibrosis using fxr ligands |
| 12/27/2006 | EP1734969A2 Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (ryr2) and uses thereof |
| 12/27/2006 | EP1734968A2 Use of 9h-purine-2,6-diamine derivatives in the treatment of proliferative diseases and novel 9h-purine-2,6-diamine derivatives |
| 12/27/2006 | EP1734967A2 Pyrrolo [2,3-d] pyrimidine compounds for treating transplant rejection |
| 12/27/2006 | EP1734966A2 Piperizinylpiperidine derivatives as chemokine receptor antagonists |
| 12/27/2006 | EP1734965A1 New compositions and methods for maintaining eyelid hygiene |
| 12/27/2006 | EP1734964A1 17 beta-acetamide-4-azasteroids as androgen receptor modulators |
| 12/27/2006 | EP1734963A2 Method of treating men with metabolic and anthropometric disorders |
| 12/27/2006 | EP1734962A2 Compositions and methods for modulating gated ion channels |
| 12/27/2006 | EP1734961A2 Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors |
| 12/27/2006 | EP1734960A1 Methods for the treatment of hypertension |
| 12/27/2006 | EP1734959A2 Method of treating schizophrenia and/or glucoregulatory abnormalities |
| 12/27/2006 | EP1734958A1 Methods for the treatment of hypertension |
| 12/27/2006 | EP1734957A2 Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders |
| 12/27/2006 | EP1734956A1 Treatment of impaired respiratory function with gaboxadol |
| 12/27/2006 | EP1734955A2 Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss |
| 12/27/2006 | EP1734954A1 Efficacious composition of a benzimidazole, an avermectin and praziquantel and related methods of use |
| 12/27/2006 | EP1734953A1 Co-formulations of kits of bioactive agents |
| 12/27/2006 | EP1734952A1 Protein kinase c inhibitors for the treatment of autoimmune diseases and of transplant rejection |
| 12/27/2006 | EP1734951A2 Diphenyl-indol-2-on compounds and their use in the treatment of cancer |
| 12/27/2006 | EP1734950A2 Treating a viral disorder |
| 12/27/2006 | EP1734949A1 Purifications of ellagitannins |
| 12/27/2006 | EP1734948A1 Tri-substitued 2-benzhydryl-5-benzlamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel 3,6-disubstituted pyran derivatives |
| 12/27/2006 | EP1734947A1 Expression of fatty acid desaturases in corn |
| 12/27/2006 | EP1734946A2 Method of using punicic acid to enhance immune response and prevent metabolic disorders |
| 12/27/2006 | EP1734945A1 A composition containing a complex comprising a metal ion and a carboxylate ligand having anti-inflammatory activity |
| 12/27/2006 | EP1734944A1 4-oxo-fenretinide, administered alone and in combination with fenretinide, as preventive and therapeutic agent for cancer |
| 12/27/2006 | EP1734943A1 Use of capsaicin and capsaicinoids for diagnosing chemical hypersensibility |
| 12/27/2006 | EP1734942A1 Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors |
| 12/27/2006 | EP1734941A2 Neural tourniquet |
| 12/27/2006 | EP1734940A1 Combination of deramciclane and opoids as analgesics |
| 12/27/2006 | EP1734939A1 Anti-parasitic compounds and methods of their use |
| 12/27/2006 | EP1734936A2 Amphiphilic star-like or scoprion-like macromolecules, various compositions and uses thereof |
| 12/27/2006 | EP1734933A1 Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423) |
| 12/27/2006 | EP1734931A2 Formulations of ramipril |
| 12/27/2006 | EP1734930A2 Low dose pharmaceutical products |
| 12/27/2006 | EP1734927A1 Pimecrolimus foam composition containing hexylene glycol, optionally oleyl alcohol, dimethylisosorbide and/or medium chain triglycerides |
| 12/27/2006 | EP1734926A2 Aqueous solutions comprising prednisolone and a cyclodextrin derivative |
| 12/27/2006 | EP1734924A1 Deferasirox dispersible tablets |
| 12/27/2006 | EP1734921A2 Coated tablet formulation and method |
| 12/27/2006 | EP1734920A2 Combination of a nmda receptor antagonist and an mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions |
| 12/27/2006 | EP1734918A1 Pharmaceutical composition for treating hair loss and benign prostatic hyperplasia |
| 12/27/2006 | EP1734821A2 Activators of hexosamine biosynthesis as inhibitors of injury induced by ischemia or hemorrhagic shock |
| 12/27/2006 | EP1734820A2 Imidazopyrazines, imidazopyridines, and imidazopyrimidines as crf1 receptor ligands |
| 12/27/2006 | EP1734819A1 Compositions and methods for targeting metastatic tumors using multivalent ligand-linked carbohydrate polymers |
| 12/27/2006 | EP1660476B1 Haloalkyl- and piperidine-substituted benzimidazole-derivatives |
| 12/27/2006 | EP1653963B1 Nasal pharmaceutical piribedil composition |
| 12/27/2006 | EP1651652B1 Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders |
| 12/27/2006 | EP1611098B1 Compounds having activity at 5ht2c receptor and uses thereof |